{
    "pmcid": "9491202",
    "qa_pairs": {
        "How can nanobodies potentially provide cross-reactivity against multiple SARS-CoV-2 variants?": [
            "By targeting conserved regions of the spike protein",
            "By binding to the viral RNA genome",
            "By inducing mutations in the viral envelope",
            "By enhancing the host's innate immune response"
        ],
        "What are nanobodies derived from, as highlighted in the paper discussing their potential against SARS-CoV-2 variants?": [
            "Camelid antibodies",
            "Human monoclonal antibodies",
            "Mouse hybridoma cells",
            "Bacterial phage display libraries"
        ],
        "What future application of nanobodies is discussed for direct delivery to the respiratory tract?": [
            "Inhalable formulations",
            "Oral tablet formulations",
            "Topical skin applications",
            "Intramuscular injections"
        ],
        "What is one proposed method to enhance the efficacy of nanobodies against the Omicron variant?": [
            "Using them in combination with other antiviral treatments",
            "Administering them via intravenous injection only",
            "Combining them with antibiotics",
            "Using them exclusively in pediatric patients"
        ],
        "What specific advantage do nanobodies have that makes them suitable for targeting the Omicron variant's spike protein?": [
            "High stability and engineered high affinity for specific viral epitopes",
            "Ability to integrate into host cell DNA",
            "Capacity to induce a strong T-cell response",
            "Enhanced ability to cross the blood-brain barrier"
        ]
    }
}